Toggle Health Problems and D

Little Vitamin D benefit if not achieve a good level (T1D in this cases) – Jan 2021

High-dose Vitamin D Supplementation on type 1 Diabetes Mellitus Patients: is there an Improvement in Glycemic Control?

Curr Diabetes Rev . 2021 Jan 5. doi: 10.2174/1573399817666210106102643


Diabetes is one of the health problems that lower existing levels of vitamin D
Diabetics need higher doses to achive the same level as non-diabetics
In addition, people with gut problems, such as many diabetics, need Gut-Friendly Vitamin D
Diabetics also need more than vitamin D mono-therapy
Weekly dosing is often Better than Daily
   Diabetic inflammation reduced by Vitamin D (30,000 IU weekly) – RCT July 2020
   Type 2 Diabetes inflammation reduced by 50,000 IU of Vitamin D bi-weekly and resistance training – RCT – June 2019
Many diseases, usch as Diabetes, need 40-60 ng
   T1 Diabetes 3X lower risk if high vitamin D (over 40 ng) – Meta-analysis Nov 2020


Overview Diabetes and vitamin D contains the following

  • Diabetes is 5X more frequent far from the equator
  • Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
  • Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
  • Sedentary people get less sun / Vitamin D
  • Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
  • Elderly get 4X less vitamin D from the same amount of sun
        Elderly also spend less time outdoors and have more clothes on
  • All items in category Diabetes and Vitamin D 535 items: both Type 1 and Type 2

Vitamin D appears to both prevent and treat diabetes

Number of articles in both categories of Diabetes and:
'This list is automatically updated''

  • Dark Skin 24;   Intervention 56;   Meta-analysis 38;   Obesity 35;  Pregnancy 44;   T1 (child) 39;  Omega-3 11;  Vitamin D Receptor 24;  Genetics 12;  Magnesium 27    Click here to see details

Some Diabetes studies

50 ng of Vitamin D fights Diabetes

T1 Diabetes


Diabetes, Metabolic Syndrome and Magnesium - many studies
Diabetic Epidemic

  • Step back to 1994. Suppose an epidemic struck the United States, causing blindness, kidney failure, and leg amputations in steadily increasing numbers.
    Suppose that in less than a decade's time, the epidemic had victimized one out of every eight people
    That epidemic is real, and its name is diabetes, now the nation's sixth leading cause of death.
    Chart from the web (2018?)

Franciane Trindade Cunha de Melo 1, Karem Mileo Felício 1, Natércia Neves Marques de Queiroz 1, Hana Andrade de Rider Brito 1, João Felício Abrahão Neto 1, Luísa Corrêa Janaú 2, Norberto Jorge Kzan de Souza Neto 1, Ana Luíza Aires Silva 1, Manuela Nascimento de Lemos 1, Maria Clara Neres Iunes de Oliveira 1, Angélica Leite de Alcântara 1, Lorena Vilhena de Moraes 1, Ícaro José Araújo de Souza 1, Nivin Mazen Said 1, Wanderson Maia da Silva 1, Gabriela Nascimento de Lemos 1, Márcia Costa Dos Santos 1, Lilian De Souza D Albuquerque Silva 1, Ana Regina Bastos Motta 1, Priscila Boaventura Barbosa de Figueiredo 1, Ana Carolina Contente Braga de Souza 1, Pedro Paulo Freire Piani 1, João Soares Felício 1

Background: Some authors evaluated the effect of VD on hyperglycemia in T1DM, but the results remain controversial. This study aims to analyze the effects of high-dose VD supplementation on T1DM patients' glycemic levels, maintaining stable doses of insulin.

Methods: Prospective, 12-week clinical trial including 67 T1DM patients, who were supplemented with high doses of cholecalciferol according to participants' VD value. Patients with VD levels below 30 ng/mL received 10,000 IU/day; those with levels between 30-60 ng/mL received 4,000 IU/day. Patients who had not achieved 25(OH)D levels > 30 ng/ml or presented insulin dose variation during the study were not analyzed.

Results: Only 46 out of 67 patients accomplished the criteria at the end of the study. There was no general improvement in the glycemic control evaluated by HbA1c (9.4 ± 2.4 vs 9.4 ± 2.6, p=NS) after VD supplementation. However, a posthoc analysis, based on HbA1c variation, identified patients who had HbA1c reduced at least 0.6% (group 1, N = 13 (28%)). In addition, a correlation between 25(OH)D levels with HbA1c and total insulin dose at the end of the study was observed (r = -0.3, p<0.05; r=-0.4, p<0.05, respectively) and a regression model demonstrated that 25(OH)D was independent of BMI, duration of T1DM and final total insulin dose, being capable of determining 9.2% of HbA1c final levels (Unstandardized B coefficient = -0.033 (CI 95%: -0.064 to -0.002), r² = 0.1, p <0.05).

Conclusion: Our data suggests that VD is not widely recommended for glycemic control. Nevertheless, specific patients might benefit from this approach.

Created by admin. Last Modification: Friday February 26, 2021 15:21:44 GMT-0000 by admin. (Version 5)